You are here: Industry Insights > NICE

News List

Long-term benefit of Qarziba uncertain, says NICE pharmatimes
May 07, 2018
The National Institute for Health and Care Excellence has ruled against the provision of NHS funding for EUSA Pharma’s neuroblastoma treatment Qarziba.
NICE no for Roche’s Alecensa pharmatimes
April 12, 2018
The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s Alecensa as a first-line treatment for lung cancer.
NICE u-turn sees Roche’s Tecentriq backed for lung cancer pharmatimes
April 10, 2018
Following an earlier negative decision NICE is now recommending NHS use of Roche’s immunotherapy Tecentriq for lung cancer.
Roche suffers Ocrevus knockback by NICE pharmafile
April 08, 2018
Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, as it managed to bring in $902 million in sales during the 2017 financial year.
Final NICE green light for Ipsen’s Cometriq pharmatimes
March 29, 2018
Ipsen’s Cometriq can now be routinely funded by the NHS to treat patients with medullary thyroid cancer (MTC) in England and Wales.
NICE rejects rare eye disease drug pharmatimes
March 22, 2018
Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for Dompé’s cenegermin as a treatment for neurotrophic keratitis, a rare eye condition.
NICE rejects rare eye disease drug pharmatimes
March 21, 2018
Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for Dompé’s cenegermin as a treatment for neurotrophic keratitis, a rare eye condition.
NICE endorses Keytruda for bladder cancer pharmatimes
March 19, 2018
MSD’s Keytruda is the first and only immunotherapy to be recommended for NHS use to treat urothelial carcinoma patients, when prior platinum-containing chemotherapy fails.
NICE minded to reject Keytruda for classical Hodgkin lymphoma pharmatimes
March 13, 2018
Cost regulators for NHS therapies in England and Wales say they are minded not to recommend funding for MSD’s Keytruda as a treatment for classical Hodgkin lymphoma, because its cost-effectiveness is uncertain
NICE u-turn on treatment for giant cell arteritis pharmatimes
March 09, 2018
Roche/Chugai’s RoActemra has now won the backing of the National Institute of Health and Care Excellence for the treatment o

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page